Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid.

Reindl-Schwaighofer, Roman; Eskandary, Farsad; Bartko, Johann; Heinzel, Andreas; Jilma, Bernd; Hecking, Manfred; Schoergenhofer, Christian

Reindl-Schwaighofer, Roman; Eskandary, Farsad; Bartko, Johann; Heinzel, Andreas; Jilma, Bernd; Hecking, Manfred; Schoergenhofer, Christian.

Afiliación

Reindl-Schwaighofer R; Department of Nephrology and Dialysis, Division of Medicine III, Medical University of Vienna, Vienna, Austria.
Eskandary F; Department of Nephrology and Dialysis, Division of Medicine III, Medical University of Vienna, Vienna, Austria.
Bartko J; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Heinzel A; Department of Nephrology and Dialysis, Division of Medicine III, Medical University of Vienna, Vienna, Austria.
Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Hecking M; Department of Nephrology and Dialysis, Division of Medicine III, Medical University of Vienna, Vienna, Austria.
Schoergenhofer C; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Front Med (Lausanne) ; 9: 856891, 2022.

Article en En | MEDLINE | ID: mdl-35308535

Palabras clave

Angiotensin-Converting Enzyme 2; Renin-Angiotensin-Aldosterone System; acute lung injury; fibrin degradation products; randomized controlled trial

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Austria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google